|
| 36828596 | Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community Study. | J Mol Diagn | 2023 |
| 34979999 | Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. | BMC Cancer | 2022 |
| 35351890 | Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer. | Nat Commun | 2022 |
| 35643464 | Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. | BMC Cancer | 2022 |
| 35388408 | Privacy preserving validation for multiomic prediction models. | Brief Bioinform | 2022 |
| 36575215 | The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. | NPJ Precis Oncol | 2022 |
| 34320344 | A pan-cancer organoid platform for precision medicine. | Cell Rep | 2021 |
| 33531613 | DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy. | NPJ Digit Med | 2021 |
| 33929890 | BloodPAC Data Commons for Liquid Biopsy Data. | JCO Clin Cancer Inform | 2021 |
| 32487991 | Stratification and prediction of drug synergy based on target functional similarity. | NPJ Syst Biol Appl | 2020 |
| 31953314 | Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. | Clin Cancer Res | 2020 |
| 33205120 | Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens. | Patterns (N Y) | 2020 |
| 31048689 | MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF<sup>V600E</sup> amplification whereas KRAS<sup>G13D</sup> amplification promotes EMT-chemoresistance. | Nat Commun | 2019 |
| 31727888 | Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. | Nat Commun | 2019 |
| 31209238 | Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. | Nat Commun | 2019 |
| 31080552 | Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in <i>Brca2</i>-mutant mammary tumours. | Oncotarget | 2019 |
| 30297535 | Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. | Cancer Res | 2018 |
| 27965317 | Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia. | Cancer Res | 2017 |
| 29296181 | Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. | Oncotarget | 2017 |
| 29245897 | Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum. | Oncotarget | 2017 |
| 29092942 | PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. | Cancer Res | 2017 |
| 27733477 | Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors. | Clin Cancer Res | 2017 |
| 26781748 | Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs. | BMC Genomics | 2016 |
| 26578606 | BubbleTree: an intuitive visualization to elucidate tumoral aneuploidy and clonality using next generation sequencing data. | Nucleic Acids Res | 2016 |
| 27887656 | Looking beyond the cancer cell for effective drug combinations. | Genome Med | 2016 |
| 27573426 | AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. | Mol Cancer Ther | 2016 |
| 27550940 | Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. | Mol Cancer Ther | 2016 |
| 27060149 | VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. | Nucleic Acids Res | 2016 |
| 27112209 | Defining actionable mutations for oncology therapeutic development. | Nat Rev Cancer | 2016 |
| 25944621 | A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. | Oncotarget | 2015 |
| 25870145 | Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. | Cancer Res | 2015 |
| 24170544 | Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. | Clin Cancer Res | 2014 |
| 23840389 | RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib. | PLoS One | 2013 |
| 21447798 | Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | Sci Signal | 2011 |
| 21674991 | A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. | Sci Signal | 2011 |
| 21428919 | Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. | Biochem Soc Trans | 2011 |
| 20215513 | Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). | Cancer Res | 2010 |
| 16478661 | A bio-basis function neural network for protein peptide cleavage activity characterisation. | Neural Netw | 2006 |
| 14642665 | Searching for discrimination rules in protease proteolytic cleavage activity using genetic programming with a min-max scoring function. | Biosystems | 2003 |